Clinical Trials
27 trialsNCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT06910657 2026-03-02
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Phase 1 Recruiting
NCT04373564 2026-01-22
ODYSSEY
Guerbet
Phase 4 Recruiting
NCT03746431 2026-01-07
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
Phase 1 Terminated
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT06943521 2025-12-11
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
Phase 1/2 Recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT06577987 2025-09-15
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
Phase 1 Recruiting
NCT02437318 2025-02-13
SOLAR-1
Novartis
Phase 3 Completed
NCT03906331 2025-01-17
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
Approved for marketing
NCT05500508 2024-12-24
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Phase 1/2 Terminated
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT02422615 2023-11-30
MONALEESA-3
Novartis
Phase 3 Completed
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT00986661 2022-11-02
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Provectus Pharmaceuticals
Phase 1 Unknown
NCT01772004 2021-12-20
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
EMD Serono
Phase 1 Completed
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT03050398 2020-05-28
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Novartis
Phase 3 Terminated
NCT03145909 2018-11-29
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
AbbVie
Phase 1 Terminated
NCT00753415 2015-03-17
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00006368 2013-05-01
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Phase 1 Completed
NCT00423254 2010-08-03
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Phase 1 Completed